India, Nov. 2 -- Enlivex Ltd. (ENLV), a biotechnology company developing therapies for inflammatory conditions associated with aging, announced positive 12-month topline results from the Phase IIa stage of its Phase I/IIa clinical trial evaluating Allocetra in patients with moderate-to-severe knee osteoarthritis.
Allocetra is an investigational cell-based immunotherapy designed to reprogram macrophages, immune cells involved in regulating inflammation.
The treatment is being developed to address inflammatory conditions associated with aging, including age-related osteoarthritis.
In the trial, 79.2% of patients aged 64 and older who received Allocetra achieved a clinically meaningful reduction in pain and improvement in knee function at 1...